Keocyt Report issue

For profit Phase 2
Founded: Malakoff France (2006)
Status: Acquired by RIEMSER Arzneimittel GmbH (2014) → now Esteve Labs (2020)

Organization Overview

First Clinical Trial
2017
NCT03240731
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Keocyt

Active Ingredients

Drugs in Phase 2 Trials (1)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1